Q2 2026 saw double-digit revenue growth, record gross margin, and a return to profitability, led by strong adoption in pain and appendage management. Guidance for 2026 was raised, with continued investment in innovation and clinical trials supporting long-term growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.